ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies

Post time 2024-3-13 09:18:10

journal：Molecular Cancer Therapeutics

Authors：Adam S. Chervin; Jennifer D. Stone; Iwona Konieczna; Kelly M. Calabrese; Ningyan Wang; Dipica Haribhai; Feng Dong; Michael K. White; Luis E. Rodriguez; Gail T. Bukofzer; Paul A. Ellis; Cormac Cosgrove; Claudie Hecquet; Jerry D. Clarin; Joann P. Palma; Edward B. Reilly

Published date：2023-8-1

DOI：10.1158/1535-7163.mct-22-0770

PDF link：https://aacrjournals.org/mct/art ... 795/mct-22-0770.pdf

Article link：http://dx.doi.org/10.1158/1535-7163.mct-22-0770

Article Source：American Association for Cancer Research (AACR)。

Remark：

Post time 2024-3-13 09:18:11

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AACR] ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[AACR] ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies Copy